Loading company…
Radio Medical develops targeted anti-cancer drugs, including compounds aimed at inhibiting STAT3.
Radio Medical researches and develops targeted anti-cancer drugs, including compounds aimed at inhibiting STAT3, for conditions including breast, liver, and lung cancer. Founded in 2014 and based in Kaifeng, China, it closed a Series A funding round in November 2024. The company holds 14 authorized Chinese invention patents, 3 utility model patents, and 7 registered software copyrights.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in